NASDAQ:TLPH Talphera Q3 2026 Earnings Date & Estimates $1.09 0.00 (0.00%) As of 03:11 PM Eastern This is a fair market value price provided by Massive. Learn more. Talphera is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 12, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Talphera in Q3 2026Talphera is expected to post earnings of -$0.06 per share. In the same quarter a year earlier Talphera reported -$0.11 per share. Talphera last reported on August 13, 2026, posting -$0.06 per share and beating the -$0.0625 consensus estimate. Talphera has beaten the consensus EPS estimate in 8 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.06Prior-Year EPS-$0.11Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.06 (Beat by +$0.0025)EPS Beat Rate8 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Talphera Q3 2026 Earnings FAQ When does Talphera report Q3 2026 earnings? Talphera (NASDAQ:TLPH) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Talphera's Q3 2026 earnings call? Talphera's Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Talphera? Analysts expect Talphera to post earnings of -$0.06 per share for Q3 2026. Talphera Earnings HeadlinesTalphera to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026November 4, 2026 | prnewswire.comTalphera (TLPH) Stock Forecast & Price TargetSeptember 30, 2026 | investing.comWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.November 10 at 1:00 AM | Porter & Company (Ad)Talphera (TLPH) upgraded to buy: Here's what you should knowSeptember 21, 2026 | msn.comTalphera to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 3, 2026 | prnewswire.comTalphera Earnings Call Highlights Nafamostat MomentumAugust 23, 2026 | tipranks.comSee More Talphera Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Talphera? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Talphera and other key companies, straight to your email. Email Address About TalpheraTalphera (NASDAQ:TLPH), formerly known as AcelRx Pharmaceuticals, is a specialty pharmaceutical company focused on developing and commercializing therapies for acute pain. The company’s lead product is DSUVIA, a sublingual tablet containing sufentanil, an opioid analgesic designed to provide rapid relief for adults experiencing acute pain severe enough to require an opioid. DSUVIA is intended for use in medically supervised settings, including hospitals, surgical centers and other certified health-care environments. The product is administered under the supervision of trained health-care professionals and is not designed for outpatient or home use. Talphera has positioned DSUVIA as an option for situations in which intravenous access may be impractical or undesirable. The company’s development history also includes Zalviso, a patient-controlled sublingual sufentanil delivery system that was approved in Europe for the management of acute pain in hospital settings. Talphera’s activities have primarily centered on the United States and selected international markets, although product availability and commercial arrangements may vary by region. No additional current leadership information is included here because reliable details were not available.View Talphera ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
